Use of Amino-Terminal Pro–B-Type Natriuretic Peptide to Guide Outpatient Therapy of Patients With Chronic Left Ventricular Systolic Dysfunction
| Autor: | Jordan T. Shin, William D. Carlson, Annabel Chen-Tournoux, Kimberly A. Parks, Rory B. Weiner, Jane E. Marshall, Shanmugam Uthamalingam, Thomas J. Wang, Gregory D. Lewis, Han Na Kim, Dorothy Sullivan, Asim A. Mohammed, Shawn A. Gregory, James L. Januzzi, Stephanie A. Moore, Marc J. Semigran, Justine Barajas, Shafiq U. Rehman, Anju Bhardwaj, Aaron L. Baggish, Linda Barajas |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
medicine.medical_specialty
medicine.drug_class heart failure Kaplan-Meier Estimate outcomes Gee Ventricular Dysfunction Left Quality of life Internal medicine Natriuretic Peptide Brain Clinical endpoint Natriuretic peptide Ambulatory Care Medicine Humans Prospective Studies Generalized estimating equation Aged Ultrasonography Ejection fraction business.industry Standard of Care Middle Aged medicine.disease Peptide Fragments Treatment Outcome Heart failure Chronic Disease Cardiology Quality of Life End-diastolic volume Female business Cardiology and Cardiovascular Medicine natriuretic peptides |
| Zdroj: | Journal of the American College of Cardiology. (18):1881-1889 |
| ISSN: | 0735-1097 |
| DOI: | 10.1016/j.jacc.2011.03.072 |
| Popis: | Objectives The aim of this study was to evaluate whether chronic heart failure (HF) therapy guided by concentrations of amino-terminal pro–B-type natriuretic peptide (NT-proBNP) is superior to standard of care (SOC) management. Background It is unclear whether standard HF treatment plus a goal of reducing NT-proBNP concentrations improves outcomes compared with standard management alone. Methods In a prospective single-center trial, 151 subjects with HF due to left ventricular (LV) systolic dysfunction were randomized to receive either standard HF care plus a goal to reduce NT-proBNP concentrations ≤1,000 pg/ml or SOC management. The primary endpoint was total cardiovascular events between groups compared using generalized estimating equations. Secondary endpoints included effects of NT-proBNP–guided care on patient quality of life as well as cardiac structure and function, assessed with echocardiography. Results Through a mean follow-up period of 10 ± 3 months, a significant reduction in the primary endpoint of total cardiovascular events was seen in the NT-proBNP arm compared with SOC (58 events vs. 100 events, p = 0.009; logistic odds for events 0.44, p = 0.02); Kaplan-Meier curves demonstrated significant differences in time to first event, favoring NT-proBNP–guided care (p = 0.03). No age interaction was found, with elderly patients benefitting similarly from NT-proBNP–guided care as younger subjects. Compared with SOC, NT-proBNP–guided patients had greater improvements in quality of life, demonstrated greater relative improvements in LV ejection fraction, and had more significant improvements in both LV end-systolic and -diastolic volume indexes. Conclusions In patients with HF due to LV systolic dysfunction, NT-proBNP–guided therapy was superior to SOC, with reduced event rates, improved quality of life, and favorable effects on cardiac remodeling. (Use of NT-proBNP Testing to Guide Heart Failure Therapy in the Outpatient Setting; NCT00351390 ) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|